{"id":"W4402558540","doi":"10.1016/j.annonc.2024.08.2251","title":"LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Loxo Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Genentech; Veracyte; Pfizer; Incyte; Mersana Therapeutics; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Eli Lilly and Company; National Comprehensive Cancer Network; Medac; Jazz Pharmaceuticals; Puma Biotechnology; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Radius Health; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Celgene","keywords":"Medicine; Aromatase inhibitor; Breast cancer; Internal medicine; Nonsteroidal; Adjuvant; Oncology; Aromatase; Cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001551411,0.0009343553,0.001656565,0.0002191178,0.0001931338,0.001025901,0.000680377,0.0006829837,0.003072345],"category_scores_gemma":[0.001302059,0.0002852309,0.00242787,0.0004108546,0.0005725502,0.0008733128,0.0006468185,0.002252151,0.0008271131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008813731,"about_ca_system_score_gemma":0.0009290967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001394979,"about_ca_topic_score_gemma":0.006310784,"domain_scores_codex":[0.9994468,0.0002804384,0.000034777,0.00008304199,0.00004964346,0.0001052008],"domain_scores_gemma":[0.999401,0.0001438745,0.0001770172,0.0000780573,0.00003829146,0.0001618622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8556567,0.004047957,0.03099014,0.001497441,0.00860554,0.0001839103,0.0001229197,0.002910661,0.005003298,0.0004682346,0.00724296,0.08327038],"study_design_scores_gemma":[0.6112477,0.1468863,0.1931625,0.0009120961,0.01942913,0.0008023584,0.0003952042,0.00398863,0.002982935,0.00221457,0.01780162,0.0001769908],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796233,0.01165302,0.0003065721,0.001220152,0.0002675461,0.0002808743,0.003220608,0.00006330172,0.003364643],"genre_scores_gemma":[0.9794694,0.005759216,0.0006508495,0.001682549,0.0003104547,0.0004996164,0.007618594,0.00003176483,0.003977539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003072345,"threshold_uncertainty_score":0.01027805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03707574296529653,"score_gpt":0.3526388762594793,"score_spread":0.3155631332941828,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}